Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $169 from $175 and keeps a Neutral rating on the shares. The firm said discrete customer decisions to defer ramps on new product intros, combined with capital goods demand softnes at year-end 2024 all contributing to revisions.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks